{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:43:22Z","timestamp":1778107402352,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-023-05510-0","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T01:01:11Z","timestamp":1698022871000},"page":"2613-2619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sickle cell disease: combination new therapies vs. CRISPR-Cas9 potential and challenges \u2014 review article"],"prefix":"10.1007","volume":"103","author":[{"given":"Ilham","family":"Youssry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1482-7792","authenticated-orcid":false,"given":"Nardeen","family":"Ayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"5510_CR1","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1182\/blood-2010-01-251348","volume":"115","author":"W DavidJ","year":"2010","unstructured":"DavidJ W (2010) The inherited diseases of hemoglobin are an emerging global health burden. Blood 115:4331\u20134336. https:\/\/doi.org\/10.1182\/blood-2010-01-251348","journal-title":"Blood"},{"key":"5510_CR2","unstructured":"CDC (2020) Data & Statistics on Sickle Cell Disease | CDC. In: Cent. Dis. Control Prev. https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html. Accessed 1 Nov 2021"},{"key":"5510_CR3","unstructured":"Sedrak A, Kondamudi NP (2023) Sickle cell disease. In: StatPearls. StatPearls Publishing.\u00a0http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482384\/"},{"key":"5510_CR4","doi-asserted-by":"publisher","unstructured":"Pecker LH, Lanzkron S (2021) Sickle cell disease. Ann Intern Med 174:ITC1\u2013ITC16. https:\/\/doi.org\/10.7326\/AITC202101190","DOI":"10.7326\/AITC202101190"},{"key":"5510_CR5","doi-asserted-by":"publisher","first-page":"e27423","DOI":"10.1002\/pbc.27423","volume":"65","author":"LM Hilliard","year":"2018","unstructured":"Hilliard LM, Kulkarni V, Sen B et al (2018) Red blood cell transfusion therapy for sickle cell patients with frequent painful events. Pediatr Blood Cancer 65:e27423. https:\/\/doi.org\/10.1002\/pbc.27423","journal-title":"Pediatr Blood Cancer"},{"key":"5510_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJM199807023390102","volume":"339","author":"RJ Adams","year":"1998","unstructured":"Adams RJ, McKie VC, Hsu L et al (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339:5\u201311. https:\/\/doi.org\/10.1056\/NEJM199807023390102","journal-title":"N Engl J Med"},{"key":"5510_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1067\/mpd.2002.122498","volume":"140","author":"DJ Scothorn","year":"2002","unstructured":"Scothorn DJ, Price C, Schwartz D et al (2002) Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 140:348\u2013354. https:\/\/doi.org\/10.1067\/mpd.2002.122498","journal-title":"J Pediatr"},{"key":"5510_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2010-01-261123","volume":"117","author":"ML Hulbert","year":"2011","unstructured":"Hulbert ML, McKinstry RC, Lacey JL et al (2011) Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 117:772\u2013779. https:\/\/doi.org\/10.1182\/blood-2010-01-261123","journal-title":"Blood"},{"key":"5510_CR9","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","volume":"119","author":"RE Ware","year":"2012","unstructured":"Ware RE, Helms RW (2012) Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood 119:3925\u20133932. https:\/\/doi.org\/10.1182\/blood-2011-11-392340","journal-title":"Blood"},{"key":"5510_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1172\/JCI200316672","volume":"111","author":"VP Cokic","year":"2003","unstructured":"Cokic VP, Smith RD, Beleslin-Cokic BB et al (2003) Hydroxyurea induces fetal hemoglobin by the nitric oxide\u2013dependent activation of soluble guanylyl cyclase. J Clin Invest 111:231\u2013239. https:\/\/doi.org\/10.1172\/JCI200316672","journal-title":"J Clin Invest"},{"key":"5510_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12288-013-0261-4","volume":"30","author":"RK Agrawal","year":"2014","unstructured":"Agrawal RK, Patel RK, shah V, et al (2014) Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus 30:91\u201396. https:\/\/doi.org\/10.1007\/s12288-013-0261-4","journal-title":"Indian J Hematol Blood Transfus"},{"key":"5510_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1715971","volume":"379","author":"Y Niihara","year":"2018","unstructured":"Niihara Y, Miller ST, Kanter J et al (2018) A phase 3 trial of L-glutamine in sickle cell disease. N Engl J Med 379:226\u2013235. https:\/\/doi.org\/10.1056\/NEJMoa1715971","journal-title":"N Engl J Med"},{"key":"5510_CR13","doi-asserted-by":"publisher","first-page":"e24920","DOI":"10.7759\/cureus.24920","volume":"14","author":"MH Dick","year":"2022","unstructured":"Dick MH, Abdelgadir A, Kulkarni VV et al (2022) Comparing the safety and efficacy of L-glutamine, voxelotor, and crizanlizumab for reducing the frequency of vaso-occlusive crisis in sickle cell disease: a systematic review. Cureus 14:e24920. https:\/\/doi.org\/10.7759\/cureus.24920","journal-title":"Cureus"},{"key":"5510_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","volume":"376","author":"KI Ataga","year":"2017","unstructured":"Ataga KI, Kutlar A, Kanter J et al (2017) Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 376:429\u2013439. https:\/\/doi.org\/10.1056\/NEJMoa1611770","journal-title":"N Engl J Med"},{"key":"5510_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2147\/JBM.S191423","volume":"10","author":"TR Riley","year":"2019","unstructured":"Riley TR, Riley TT (2019) Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date. J Blood Med 10:307\u2013311. https:\/\/doi.org\/10.2147\/JBM.S191423","journal-title":"J Blood Med"},{"key":"5510_CR16","doi-asserted-by":"publisher","first-page":"204062072110011","DOI":"10.1177\/20406207211001136","volume":"12","author":"AK Glaros","year":"2021","unstructured":"Glaros AK, Razvi R, Shah N, Zaidi AU (2021) Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. Ther Adv Hematol 12:20406207211001136. https:\/\/doi.org\/10.1177\/20406207211001136","journal-title":"Ther Adv Hematol"},{"key":"5510_CR17","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1182\/blood-2021-153138","volume":"138","author":"N Shah","year":"2021","unstructured":"Shah N, Lipato T, Alvarez OA et al (2021) Real-world experience of voxelotor for the management of complications in sickle cell disease. Blood 138:2052. https:\/\/doi.org\/10.1182\/blood-2021-153138","journal-title":"Blood"},{"key":"5510_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1903212","volume":"381","author":"E Vichinsky","year":"2019","unstructured":"Vichinsky E, Hoppe CC, Ataga KI et al (2019) A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med 381:509\u2013519. https:\/\/doi.org\/10.1056\/NEJMoa1903212","journal-title":"N Engl J Med"},{"key":"5510_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1182\/blood-2021-145398","volume":"138","author":"JZ Xu","year":"2021","unstructured":"Xu JZ, Conrey A, Frey I et al (2021) Mitapivat (AG-348) Demonstrates safety, tolerability, and improvements in anemia, hemolysis, oxygen affinity, and hemoglobin s polymerization kinetics in adults with sickle cell disease: a phase 1 dose escalation study. Blood 138:10. https:\/\/doi.org\/10.1182\/blood-2021-145398","journal-title":"Blood"},{"key":"5510_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1124\/jpet.121.000743","volume":"380","author":"P Schroeder","year":"2022","unstructured":"Schroeder P, Fulzele K, Forsyth S et al (2022) Etavopivat, a pyruvate kinase activator in red blood cells, for the treatment of sickle cell disease. J Pharmacol Exp Ther 380:210\u2013219. https:\/\/doi.org\/10.1124\/jpet.121.000743","journal-title":"J Pharmacol Exp Ther"},{"key":"5510_CR21","doi-asserted-by":"publisher","first-page":"E226","DOI":"10.1002\/ajh.26554","volume":"97","author":"MJ van Dijk","year":"2022","unstructured":"van Dijk MJ, Rab MAE, van Oirschot BA et al (2022) Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study. Am J Hematol 97:E226\u2013E229. https:\/\/doi.org\/10.1002\/ajh.26554","journal-title":"Am J Hematol"},{"key":"5510_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fphys.2020.00577","volume":"11","author":"ML Kalev-Zylinska","year":"2020","unstructured":"Kalev-Zylinska ML, Hearn JI, Makhro A, Bogdanova A (2020) N-Methyl-D-aspartate receptors in hematopoietic cells: what have we learned? Front Physiol 11:577. https:\/\/doi.org\/10.3389\/fphys.2020.00577","journal-title":"Front Physiol"},{"key":"5510_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/jha2.11","volume":"1","author":"A Mahkro","year":"2020","unstructured":"Mahkro A, Hegemann I, Seiler E et al (2020) A pilot clinical phase II trial MemSID: acute and durable changes of red blood cells of sickle cell disease patients on memantine treatment. EJHaem 1:23\u201334. https:\/\/doi.org\/10.1002\/jha2.11","journal-title":"EJHaem"},{"key":"5510_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/01.HS9.0000821396.84589.71","volume":"6","author":"M Tarasev","year":"2022","unstructured":"Tarasev M, Herppich A, Gao X, Hines P (2022) S107: P-Selectin inhibitor inclacumab reduces cell adhesion in an in-vitro assays showing potential for prevention of vaso-occlusion events in sickle cell disease. HemaSphere 6:3\u20134. https:\/\/doi.org\/10.1097\/01.HS9.0000821396.84589.71","journal-title":"HemaSphere"},{"key":"5510_CR25","unstructured":"Global Blood Therapeutics (2023) A randomized, double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of inclacumab in participants with sickle cell disease experiencing vaso-occlusive crises.\u00a0(Clinical Trial Registration NCT04935879). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04935879"},{"key":"5510_CR26","unstructured":"Assistance Publique - H\u00f4pitaux de Paris (2022) Interest of famotidine in reducing endothelial expression of P-selectin in children with sickle cell disease: pilot study, single-center, prospective, non-comparative.(Clinical Trial Registration NCT05084521). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05084521"},{"key":"5510_CR27","doi-asserted-by":"publisher","first-page":"103555","DOI":"10.1016\/j.transci.2022.103555","volume":"61","author":"MT Lee","year":"2022","unstructured":"Lee MT, Ogu UO (2022) Sickle cell disease in the new era: advances in drug treatment. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 61:103555. https:\/\/doi.org\/10.1016\/j.transci.2022.103555","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"5510_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fphys.2020.00435","volume":"11","author":"G Salinas Cisneros","year":"2020","unstructured":"Salinas Cisneros G, Thein SL (2020) Recent advances in the treatment of sickle cell disease. Front Physiol 11:435. https:\/\/doi.org\/10.3389\/fphys.2020.00435","journal-title":"Front Physiol"},{"key":"5510_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.exphem.2020.08.008","volume":"92","author":"MA Ali","year":"2020","unstructured":"Ali MA, Ahmad A, Chaudry H et al (2020) Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol 92:11. https:\/\/doi.org\/10.1016\/j.exphem.2020.08.008","journal-title":"Exp Hematol"},{"key":"5510_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/ajh.24975","volume":"93","author":"RP Hebbel","year":"2018","unstructured":"Hebbel RP, Hedlund BE (2018) Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks. Am J Hematol 93:321\u2013325. https:\/\/doi.org\/10.1002\/ajh.24975","journal-title":"Am J Hematol"},{"key":"5510_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.17312","volume":"194","author":"BS Pace","year":"2021","unstructured":"Pace BS, Starlard-Davenport A, Kutlar A (2021) Sickle cell disease: progress towards combination drug therapy. Br J Haematol 194:240\u2013251. https:\/\/doi.org\/10.1111\/bjh.17312","journal-title":"Br J Haematol"},{"key":"5510_CR32","first-page":"1790","volume":"93","author":"GF Atweh","year":"1999","unstructured":"Atweh GF, Sutton M, Nassif I et al (1999) Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 93:1790\u20131797","journal-title":"Blood"},{"key":"5510_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1126\/science.1211053","volume":"334","author":"J Xu","year":"2011","unstructured":"Xu J, Peng C, Sankaran VG et al (2011) Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science 334:993\u2013996. https:\/\/doi.org\/10.1126\/science.1211053","journal-title":"Science"},{"key":"5510_CR34","unstructured":"EMA (2023) Revocation of authorisation for sickle cell disease medicine Adakveo. In: Eur. Med. Agency. https:\/\/www.ema.europa.eu\/en\/news\/revocation-authorisation-sickle-cell-disease-medicine-adakveo. Accessed 16 Sep 2023"},{"key":"5510_CR35","doi-asserted-by":"crossref","unstructured":"Crizanlizumab versus placebo, with or without hydroxyurea\/hydroxycarbamide, in adolescent and adult patients with sickle cell disease and vaso-occlusive crises: a randomized, double-blind, phase III study (STAND) | Blood | American Society of Hematology. https:\/\/ashpublications.org\/blood\/article\/134\/Supplement_1\/998\/427181\/Crizanlizumab-Versus-Placebo-with-or-without. Accessed 16 Sep 2023","DOI":"10.1182\/blood-2019-125775"},{"key":"5510_CR36","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJM198409203111207","volume":"311","author":"FL Johnson","year":"1984","unstructured":"Johnson FL, Look AT, Gockerman J et al (1984) Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 311:780\u2013783. https:\/\/doi.org\/10.1056\/NEJM198409203111207","journal-title":"N Engl J Med"},{"key":"5510_CR37","doi-asserted-by":"publisher","first-page":"1036939","DOI":"10.3389\/fmed.2023.1036939","volume":"10","author":"N Bhalla","year":"2023","unstructured":"Bhalla N, Bhargav A, Yadav SK, Singh AK (2023) Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: a review. Front Med 10:1036939. https:\/\/doi.org\/10.3389\/fmed.2023.1036939","journal-title":"Front Med"},{"key":"5510_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/bmt.2014.84","volume":"49","author":"M Bhatia","year":"2014","unstructured":"Bhatia M, Jin Z, Baker C et al (2014) Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant 49:913\u2013920. https:\/\/doi.org\/10.1038\/bmt.2014.84","journal-title":"Bone Marrow Transplant"},{"key":"5510_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2014.7192","volume":"312","author":"MM Hsieh","year":"2014","unstructured":"Hsieh MM, Fitzhugh CD, Weitzel RP et al (2014) Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 312:48\u201356. https:\/\/doi.org\/10.1001\/jama.2014.7192","journal-title":"JAMA"},{"key":"5510_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(04)16628-2","volume":"364","author":"DA Jacobsohn","year":"2004","unstructured":"Jacobsohn DA, Duerst R, Tse W, Kletzel M (2004) Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet Lond Engl 364:156\u2013162. https:\/\/doi.org\/10.1016\/S0140-6736(04)16628-2","journal-title":"Lancet Lond Engl"},{"key":"5510_CR41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.bbmt.2015.08.036","volume":"22","author":"SL Saraf","year":"2016","unstructured":"Saraf SL, Oh AL, Patel PR et al (2016) Nonmyeloablative stem cell transplantation with alemtuzumab\/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 22:441\u2013448. https:\/\/doi.org\/10.1016\/j.bbmt.2015.08.036","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5510_CR42","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","volume":"130","author":"CD Fitzhugh","year":"2017","unstructured":"Fitzhugh CD, Cordes S, Taylor T et al (2017) At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood 130:1946\u20131948. https:\/\/doi.org\/10.1182\/blood-2017-03-772392","journal-title":"Blood"},{"key":"5510_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bmt.1701291","volume":"22","author":"C Vermylen","year":"1998","unstructured":"Vermylen C, Cornu G, Ferster A et al (1998) Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 22:1\u20136. https:\/\/doi.org\/10.1038\/sj.bmt.1701291","journal-title":"Bone Marrow Transplant"},{"key":"5510_CR44","first-page":"1918","volume":"95","author":"MC Walters","year":"2000","unstructured":"Walters MC, Storb R, Patience M et al (2000) Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 95:1918\u20131924","journal-title":"Blood"},{"key":"5510_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/bloodadvances.2022008137","volume":"7","author":"A Leonard","year":"2023","unstructured":"Leonard A, Furstenau D, Abraham A et al (2023) Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease. Blood Adv 7:227\u2013234. https:\/\/doi.org\/10.1182\/bloodadvances.2022008137","journal-title":"Blood Adv"},{"key":"5510_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1182\/bloodadvances.2017012005","volume":"2","author":"J Gaziev","year":"2018","unstructured":"Gaziev J, Isgr\u00f2 A, Sodani P et al (2018) Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCR\u03b1\u03b2+\/CD19+-depleted grafts. Blood Adv 2:263\u2013270. https:\/\/doi.org\/10.1182\/bloodadvances.2017012005","journal-title":"Blood Adv"},{"key":"5510_CR47","doi-asserted-by":"publisher","first-page":"551170","DOI":"10.3389\/fped.2020.551170","volume":"8","author":"L Krishnamurti","year":"2021","unstructured":"Krishnamurti L (2021) Hematopoietic cell transplantation for sickle cell disease. Front Pediatr 8:551170. https:\/\/doi.org\/10.3389\/fped.2020.551170","journal-title":"Front Pediatr"},{"key":"5510_CR48","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1182\/blood-2012-07-441493","volume":"121","author":"E Ophir","year":"2013","unstructured":"Ophir E, Or-Geva N, Gurevich I et al (2013) Murine anti\u2013third-party central-memory CD8+ T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells. Blood 121:1220\u20131228. https:\/\/doi.org\/10.1182\/blood-2012-07-441493","journal-title":"Blood"},{"key":"5510_CR49","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/s41409-021-01237-6","volume":"56","author":"AK Singh","year":"2021","unstructured":"Singh AK, Schetzen E, Yadav SK et al (2021) Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells. Bone Marrow Transplant 56:1818\u20131827. https:\/\/doi.org\/10.1038\/s41409-021-01237-6","journal-title":"Bone Marrow Transplant"},{"key":"5510_CR50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD et al (2021) CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med 384:252\u2013260. https:\/\/doi.org\/10.1056\/NEJMoa2031054","journal-title":"N Engl J Med"},{"key":"5510_CR51","doi-asserted-by":"publisher","first-page":"103060","DOI":"10.1016\/j.transci.2021.103060","volume":"60","author":"SH Park","year":"2021","unstructured":"Park SH, Bao G (2021) CRISPR\/Cas9 gene editing for curing sickle cell disease. Transfus Apher Sci 60:103060. https:\/\/doi.org\/10.1016\/j.transci.2021.103060","journal-title":"Transfus Apher Sci"},{"key":"5510_CR52","series-title":"stem cells: translational science to therapy","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/5584_2018_331","volume-title":"Cell biology and translational medicine","author":"S Demirci","year":"2019","unstructured":"Demirci S, Leonard A, Haro-Mora JJ et al (2019) CRISPR\/Cas9 for sickle cell disease: applications, future possibilities, and challenges. In: Turksen K (ed) Cell biology and translational medicine, vol 5. stem cells: translational science to therapy. Springer International Publishing, Cham, pp 37\u201352"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05510-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05510-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05510-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T17:02:22Z","timestamp":1722099742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05510-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5510"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05510-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"assertion":[{"value":"16 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. Therefore, informed consent was not needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors have participated in the formulation of this review and agree to its contents. This type of study \u201creview article\u201d includes and summarizes data originally published by other authors all referenced in this study, and it is not otherwise under active review by any other publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}